{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:38:49Z","timestamp":1792640329218,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This study aimed to characterize the safety and efficacy of DC-CIK therapy in two patients with previously treated chronic lymphocytic leukemia or peritoneal cancer, respectively. Participants had received conventional chemotherapy treatment for their specific cancers, and in addition, 1\u20132 treatments of DC-CIK therapy were administered to subjects over the course of 1 year. Subject A received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and a repeat dosage 6 months later. Subject B received an initial dosage of 3 intravenous infusions of DC-CIK therapy on three successive days and received further chemotherapy after approximately 1 year. No treatment-related adverse events were reported, and both patients experienced favorable outcomes from the treatment, including enhanced treatment response, increased chemotherapy tolerance, and prolonged survival in comparison to typical 5-year survival rates.<\/jats:p>","DOI":"10.3389\/fmed.2023.1240330","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:29:36Z","timestamp":1696854576000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Brian","family":"Mehling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DongCheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Santora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Mih\u00e1lyov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1089\/hum.2009.145","article-title":"Dendritic cell-based cancer gene therapy.","volume":"20","author":"Smits","year":"2009","journal-title":"Hum Gene Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14712598.2020.1728250","article-title":"DC-CIK as a widely applicable cancer immunotherapy.","volume":"20","author":"Wang","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1002\/jcp.29827","article-title":"Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy.","volume":"235","author":"Zhang","year":"2020","journal-title":"J Cell Physiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1517\/14712598.2012.676037","article-title":"CIK cells\u2013current status, clinical perspectives and future prospects\u2013the good news.","volume":"12","author":"Hui","year":"2012","journal-title":"Expert Opin Biol Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jcp.28977","article-title":"Dendritic cell\/cytokine-induced killer cell-based immunotherapy in lung cancer: what we know and future landscape.","volume":"235","author":"Mohsenzadegan","year":"2020","journal-title":"J Cell Physiol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.581270","article-title":"One single site clinical study: to evaluate the safety and efficacy of immunotherapy with autologous dendritic cells, cytokine-induced killer cells in primary hepatocellular carcinoma patients.","volume":"10","author":"Xu","year":"2020","journal-title":"Front Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jcyt.2014.02.011","article-title":"Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis.","volume":"16","author":"Wang","year":"2014","journal-title":"Cytotherapy."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.1450.1450","article-title":"Clinical Study Of DC-CIK (dendritic cells and cytokine-induced killer cells) Eliminate Minimal Residual Leukemia.","volume":"122","author":"Zheng","year":"2013","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/imt-2019-0108","article-title":"5 years of clinical DC-CIK\/NK cells immunotherapy for acute myeloid leukemia \u2013 a summary.","volume":"12","author":"Zhang","year":"2020","journal-title":"Immunotherapy."},{"key":"B10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4172\/2157-7633.1000297","article-title":"Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation.","volume":"9","author":"Mehling","year":"2015","journal-title":"Int J Med Health Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.2147\/OTT.S177503","article-title":"Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen.","volume":"11","author":"Xiao","year":"2018","journal-title":"OncoTargets Ther."},{"key":"B12","first-page":"615","article-title":"Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma.","volume":"24","author":"Zhou","year":"2019","journal-title":"J BUON Off J Balk Union Oncol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024519","article-title":"Cytokine-induced killer cells\/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: a meta-analysis.","volume":"100","author":"Yuan","year":"2021","journal-title":"Medicine (Baltimore)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5473292","article-title":"Efficacy of DC-CIK immunotherapy combined with chemotherapy on locally advanced gastric cancer.","volume":"2022","author":"Liu","year":"2022","journal-title":"J Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3109\/14653240903121252","article-title":"Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery.","volume":"11","author":"Li","year":"2009","journal-title":"Cytotherapy."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1257","article-title":"The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.","volume":"10","author":"Song","year":"2021","journal-title":"Clin Transl Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1078-0432.CCR-18-2360","article-title":"Autologous dendritic cell-cytokine induced killer cell immunotherapy combined with S-1 plus cisplatin in patients with advanced gastric cancer: a prospective study.","volume":"25","author":"Qiao","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2016.57","article-title":"Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.","volume":"13","author":"Shaked","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/17474086.2018.1495557","article-title":"Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.","volume":"11","author":"Mauro","year":"2018","journal-title":"Expert Rev Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14737140.2020.1708197","article-title":"Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects.","volume":"20","author":"Rajendra","year":"2020","journal-title":"Expert Rev Anticancer Ther."},{"key":"B21","year":"2015","journal-title":"Chronic lymphocytic leukaemia (CLL) mortality statistics [Internet]. Cancer Research UK."},{"key":"B22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia. Prognostic significance.","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer."},{"key":"B23","author":"Lee","year":"2022","journal-title":"Survival statistics for chronic lymphocytic leukemia [Internet]. Canadian Cancer Society."},{"key":"B24","first-page":"364","article-title":"Effects of sorafenib combined with dendritic cells and cytokine induced killer cells on the growth and invasion and metastasis of hepatocellular carcinoma","volume":"13","author":"Qin","year":"2014","journal-title":"Chin J Dig Surg"},{"key":"B25","first-page":"553","article-title":"Clinical efficacy analysis of dendritic cell-cytokine induced killer cell immunotherapy combined with paclitaxel-cisplatin chemotherapy in patients with advanced ovarian cancer.","volume":"26","author":"Gao","year":"2021","journal-title":"J BUON Off J Balk Union Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1240330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:29:41Z","timestamp":1696854581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1240330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":25,"alternative-id":["10.3389\/fmed.2023.1240330"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1240330","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"article-number":"1240330"}}